Amberly Brown

1.4k total citations
16 papers, 906 citations indexed

About

Amberly Brown is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Amberly Brown has authored 16 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Amberly Brown's work include Vitamin D Research Studies (4 papers), Parathyroid Disorders and Treatments (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Amberly Brown is often cited by papers focused on Vitamin D Research Studies (4 papers), Parathyroid Disorders and Treatments (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Amberly Brown collaborates with scholars based in United States and Belgium. Amberly Brown's co-authors include Eduardo Slatopolsky, Cynthia S. Ritter, Paul N. MacDonald, Jane Finch, Masashi Denda, Min Zhong, W. H. OKAMURA, G.S. Reddy, David H. Perlmutter and Ernesto P. Molmenti and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Amberly Brown

14 papers receiving 863 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amberly Brown United States 10 460 310 240 193 182 16 906
Kenichi Satomura Japan 20 264 0.6× 150 0.5× 107 0.4× 131 0.7× 62 0.3× 50 890
Guerman Molostvov United Kingdom 13 587 1.3× 134 0.4× 200 0.8× 256 1.3× 57 0.3× 17 894
Leigh G. Simpson United States 11 551 1.2× 151 0.5× 155 0.6× 258 1.3× 92 0.5× 12 1.1k
Pablo Román‐García Spain 14 471 1.0× 138 0.4× 146 0.6× 142 0.7× 25 0.1× 19 700
Maria Aminoff Finland 9 154 0.3× 184 0.6× 96 0.4× 105 0.5× 51 0.3× 10 915
Lee A. Zella United States 14 89 0.2× 809 2.6× 261 1.1× 282 1.5× 112 0.6× 15 1.1k
Risul Amin Sweden 8 633 1.4× 132 0.4× 127 0.5× 348 1.8× 24 0.1× 10 923
Helena Gil‐Peña Spain 17 286 0.6× 62 0.2× 72 0.3× 87 0.5× 51 0.3× 51 755
S Dokoh Japan 16 121 0.3× 361 1.2× 84 0.3× 192 1.0× 25 0.1× 41 805
Noriko Ide Japan 12 223 0.5× 67 0.2× 61 0.3× 132 0.7× 56 0.3× 22 574

Countries citing papers authored by Amberly Brown

Since Specialization
Citations

This map shows the geographic impact of Amberly Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amberly Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amberly Brown more than expected).

Fields of papers citing papers by Amberly Brown

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amberly Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amberly Brown. The network helps show where Amberly Brown may publish in the future.

Co-authorship network of co-authors of Amberly Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Amberly Brown. A scholar is included among the top collaborators of Amberly Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amberly Brown. Amberly Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Grierson, Patrick, Rama Suresh, Andrea Wang‐Gillam, et al.. (2025). Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Clinical Cancer Research. 31(17). 3644–3651.
2.
Grierson, Patrick, Rama Suresh, Benjamin Tan, et al.. (2023). A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Clinical Cancer Research. 29(23). 4733–4739. 7 indexed citations
3.
Wang‐Gillam, Andrea, Robert R. McWilliams, Rama Suresh, et al.. (2022). Phase I dose escalation and expansion study of defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment-refractory pancreatic cancer.. Journal of Clinical Oncology. 40(16_suppl). 4146–4146. 1 indexed citations
4.
Amin, Manik, Kathryn Trinkaus, Amberly Brown, et al.. (2019). Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. Journal of Gastrointestinal Oncology. 10(3). 412–420. 7 indexed citations
5.
Chen, Ling, Kathryn Trinkaus, Andrea Wang‐Gillam, et al.. (2017). Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. Journal of Gastrointestinal Oncology. 8(6). 985–989. 15 indexed citations
6.
Bruce, Jared M., et al.. (2012). Impact of Armodafinil on Cognition in Multiple Sclerosis. Cognitive and Behavioral Neurology. 25(3). 107–114. 12 indexed citations
7.
Brown, Amberly. (2008). A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Yearbook of Neurology and Neurosurgery. 2008. 98–99.
8.
Slatopolsky, Eduardo, Adriana Dusso, & Amberly Brown. (1999). The Role of Phosphorus in the Development of Secondary Hyperparathyroidism and Parathyroid Cell Proliferation in Chronic Renal Failure. The American Journal of the Medical Sciences. 317(6). 370–370. 28 indexed citations
9.
Brown, Amberly, et al.. (1999). 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion.. PubMed. 73(1). 106–13. 92 indexed citations
10.
Brown, Amberly, et al.. (1999). 1?,25-Dihydroxy-3-Epi-vitamin D3, a natural metabolite of 1?,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. Journal of Cellular Biochemistry. 73(1). 106–113. 83 indexed citations
11.
Slatopolsky, Eduardo, Jane Finch, Masashi Denda, et al.. (1996). Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.. Journal of Clinical Investigation. 97(11). 2534–2540. 357 indexed citations
12.
Haviland, David L., William Whitehead, Ernesto P. Molmenti, et al.. (1995). Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung.. The Journal of Immunology. 154(4). 1861–1869. 208 indexed citations
13.
MacDonald, Paul N., Cynthia S. Ritter, Amberly Brown, & Eduardo Slatopolsky. (1994). Retinoic acid suppresses parathyroid hormone (PTH) secretion and PreproPTH mRNA levels in bovine parathyroid cell culture.. Journal of Clinical Investigation. 93(2). 725–730. 26 indexed citations
14.
Slatopolsky, Eduardo, et al.. (1992). Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism.. PubMed. 38. S43–9. 24 indexed citations
15.
Slatopolsky, Eduardo, et al.. (1990). The parathyroid-calcitriol axis in health and chronic renal failure.. PubMed. 29. S41–7. 45 indexed citations
16.
Brown, Amberly, et al.. (1984). Antibodies against osteosarcoma and colon cancer.. PubMed. 35–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenichi Satomura Breakdown of academic impact, for papers by Guerman Molostvov Breakdown of academic impact, for papers by Leigh G. Simpson Breakdown of academic impact, for papers by Pablo Román‐García Breakdown of academic impact, for papers by Maria Aminoff Breakdown of academic impact, for papers by Lee A. Zella Breakdown of academic impact, for papers by Risul Amin Breakdown of academic impact, for papers by Helena Gil‐Peña Breakdown of academic impact, for papers by S Dokoh Breakdown of academic impact, for papers by Noriko Ide
Rankless by CCL
2026